Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telescope InnovationsTELIF -27.31%31 3-Year ROIIC % is 172.77 as of Aug. 2025, which is 40% above its 10-year median of 123.12. GuruFocus rates TELIF with a GF Score™ of 31/100 and a GF Value™ of $0.39 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,322 Biotechnology companies, Telescope Innovations ranks better than 83.06% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Telescope Innovations's 3-Year ROIIC % for the quarter that ended in Aug. 2025 was 172.77%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Telescope Innovations's 3-Year ROIIC % or its related term are showing as below:
TELIF's 3-Year ROIIC % is ranked better than 83.06% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs TELIF: 172.77
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Telescope Innovations 3-Year ROIIC % Related Terms
Telescope Innovations 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELIF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Telescope Innovations's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's 3-Year ROIIC % falls into.
Telescope Innovations's 3-Year ROIIC % for the quarter that ended in Aug. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.977 (Aug. 2025) - -4.457 (Aug. 2022) )
/
( 3.559 (Aug. 2025) - 1.825 (Aug. 2022) )
=
3.48
/
1.734
=
200.69%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Telescope Innovations (TELIF) has a 3-Year ROIIC % of 172.77 as of Aug. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Telescope Innovations and its competitors. This is 40% above median its historical median of 123.12. Over the past decade, Telescope Innovations' 3-Year ROIIC % has ranged from 73.46 to 172.77. According to the industry distribution chart, Telescope Innovations ranks #224 out of 1322 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Telescope Innovations' 3-Year ROIIC % too high?
Telescope Innovations' current 3-Year ROIIC % of 172.77 is 40% above median its 10-year median of 123.12. Over the past 10 years, this metric has ranged from a low of 73.46 to a high of 172.77. Based on the distribution chart, Telescope Innovations ranks #224 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Telescope Innovations has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #224 out of 1322 companies for 3-Year ROIIC %. This places Telescope Innovations in the top 17% of its industry — outperforming the majority of peers. Historically, Telescope Innovations' own 3-Year ROIIC % has ranged from 73.46 to 172.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Telescope Innovations and its competitors. Telescope Innovations's current 3-Year ROIIC % is 172.77, which is 40% above median its own 10-year median of 123.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.39, compared to a current price of $0.33 — trading 15.4% below its estimated fair value. The current 3-Year ROIIC % is 172.77, which is 40% above median its 10-year median of 123.12. Telescope Innovations' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current 3-Year ROIIC % is 172.77 as of Aug. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.33 is trading 15.4% below its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Modestly Undervalued.
Key valuation signals for TELIF:
3-Year ROIIC %: 172.77 (40% above median its 10-year median of 123.12)
GF Value™: $0.39 vs. price of $0.33 (15.4% below fair value)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
31GF Score
Get the complete analysis for TELIF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
